US Patent 6,159,498: Claim Scope, Expiration, Enforceability, and Pharmaceutical Film Patent Landscape

US Patent 6,159,498 covers a two-layer, water-soluble mucosal delivery film. Its independent claim requires a hydroxyethyl cellulose, polyacrylic acid, and sodium carboxymethyl cellulose adhesive layer; a hydroxyethyl cellulose non-adhesive backing layer; and a pharmaceutical incorporated into one of those layers. The patent is directed to delivery-platform architecture, not to a particular approved drug.

The patent was granted on December 12, 2000. Based on the ordinary post-1995 patent-term rule, its nominal US term likely ended in 2018, subject to any patent-term adjustment, patent-term extension, terminal disclaimer, or earlier lapse shown in the USPTO prosecution and maintenance records.[1][2] The patent therefore presents no ordinary current US blocking position if the term has expired. Its technical disclosure remains relevant as prior art against later oral, buccal, sublingual, topical, and mucosal film patents.

What does US Patent 6,159,498 protect?

The patent protects a biodegradable, water-soluble pharmaceutical carrier device formed as a layered flexible film. Claim 1 is the controlling limitation because claims 2 through 27 depend directly or indirectly on it.

Claim 1 limitation map

Required limitation	Scope and practical meaning
Biodegradable carrier device	The device must degrade biologically. The claim does not specify a single degradation test or time period.
Water-soluble carrier device	The film must dissolve in water. A water-dispersible but insoluble product could fall outside literal scope.
Layered flexible film	The product must have at least two flexible film layers arranged as a laminate or layered structure.
First water-soluble adhesive layer	This layer contacts the mucosal surface and must dissolve in water.
Hydroxyethyl cellulose in adhesive layer	Required polymer component.
Polyacrylic acid in adhesive layer	Required polymer component, contributing to adhesion and film properties.
Sodium carboxymethyl cellulose in adhesive layer	Required polymer component.
Second water-soluble non-adhesive backing layer	The backing layer must be water-soluble and non-adhesive.
Hydroxyethyl cellulose in backing layer	Required backing-layer polymer.
Pharmaceutical in first or second layer	At least one pharmaceutical must be incorporated into either layer.

A product lacking any one of the three specified adhesive-layer polymers, or lacking hydroxyethyl cellulose in the backing layer, would not literally satisfy claim 1. A product with a single homogeneous film rather than the required adhesive and non-adhesive layers would also face a substantial literal-infringement defense.

The claim does not expressly require a particular mucosal site, dissolution time, film thickness, drug-release profile, dosage strength, manufacturing process, or commercial dosage form.

How broad is the pharmaceutical coverage?

The pharmaceutical element is broad at the independent-claim level. Claim 1 requires a pharmaceutical or combination of pharmaceuticals but does not limit the active ingredient to a named compound or therapeutic category.

Claims 2 through 25 narrow the device by adding therapeutic classes and, in most cases, lists of specific agents. These claims do not replace the layered-film limitations. A product containing one of the listed drugs infringes a dependent claim only if it also satisfies every limitation of claim 1 and the applicable dependent claim.

Therapeutic categories in claims 2 through 25

Claims	Therapeutic category	Representative listed agents
2-3	Anti-inflammatory analgesics	Acetaminophen, aspirin, diclofenac, ibuprofen, ketoprofen, naproxen, piroxicam
4-5	Steroidal anti-inflammatory agents	Hydrocortisone, prednisolone, dexamethasone, triamcinolone acetonide
6-7	Local anesthetics	Lidocaine, benzocaine, tetracaine, procaine, dibucaine
8-9	Antihistamines	Diphenhydramine, chlorpheniramine, promethazine
10-11	Bactericides	Benzalkonium chloride, chlorhexidine, povidone iodine, thymol
12-13	Vasoconstrictors	Naphazoline, tetrahydrozoline, oxymetazoline, phenylephrine
14-15	Hemostatic agents	Thrombin, tranexamic acid, aminocaproic acid, phytonadione
16-17	Chemotherapeutic agents	Sulfonamides and nitrofurazone
18-19	Antibiotics	Penicillins, cephalosporins, erythromycin, tetracycline, gentamicin
20-21	Keratolytics	Salicylic acid, podophyllum resin, podofilox, cantharidin
22-23	Cauterizing agents	Chloroacetic acid and silver nitrate
24-25	Antivirals	Acyclovir, penciclovir, valacyclovir, ganciclovir, nucleoside analogues

The lists are technically significant because they make the dependent claims unusually expansive in therapeutic coverage. They do not, however, create independent drug patents. The claims protect delivery devices containing those agents, not the active ingredients themselves.

What formulations are protected by US 6,159,498?

The protected formulation is a two-layer polymeric film with differentiated surface functions.

Adhesive mucosal layer

The first layer must contain:

Hydroxyethyl cellulose;
Polyacrylic acid; and
Sodium carboxymethyl cellulose.

This combination is central to claim scope. Hydroxyethyl cellulose and sodium carboxymethyl cellulose can contribute film formation, viscosity, water uptake, and matrix integrity. Polyacrylic acid is associated with mucoadhesive behavior through interaction with mucosal surfaces.

A formulation using polyvinylpyrrolidone, hydroxypropyl methylcellulose, carbomer, alginate, or another polymer in place of one of the required components may avoid literal infringement, depending on the product’s full composition and the construction of the claim terms.

Non-adhesive backing layer

The second layer must be water-soluble, non-adhesive, and contain hydroxyethyl cellulose. The backing limitation distinguishes the claimed structure from a single-layer mucoadhesive patch.

The claim does not state that the active ingredient must be in the adhesive layer. It may be incorporated into either the adhesive layer or the backing layer. A formulation with active ingredient in both layers is also within the express language, provided the other limitations are satisfied.

Drug-loading limitations

Claims 26 and 27 add concentration ranges:

Claim	Drug content
26	About 0.001% to about 30% by weight of the carrier device
27	About 0.005% to about 20% by weight of the carrier device

Claim 27 is narrower than claim 26. The term “about” creates a range-construction issue. Courts generally assess the ordinary meaning of the term in view of the specification, prosecution history, measurement precision, and technical context. A formulation near a boundary cannot be assessed solely by comparing a rounded label percentage.

Which claims are strongest?

Claim 1 is commercially important because it captures the platform architecture, but it is also vulnerable to invalidity challenges based on earlier mucoadhesive films, water-soluble films, polymer laminates, and pharmaceutical patches.

Claims 2 through 25 are narrower because they add active-ingredient classes or named compounds. Their practical value depends on whether the accused product uses the specified drug and the exact layered polymer structure.

Claims 26 and 27 are potentially useful in formulation disputes because they add quantitative limitations. They may be difficult to enforce where the drug percentage varies by batch, is expressed on a different basis, or is not publicly disclosed.

Claim-strength assessment

Issue	Assessment
Platform coverage	Broad as to drug categories and mucosal use
Structural limitations	Narrow because four polymer-layer requirements must be met
Chemical scope	Broad at claim 1; narrower in claims 2-25
Dose-form coverage	Focused on layered flexible films
Manufacturing coverage	No express manufacturing-method claim
Method-of-use coverage	No standalone method-of-use claim
Product-by-process exposure	Limited; the claims focus on composition and structure
Design-around potential	Meaningful through polymer substitution, single-layer construction, or different backing architecture
Current exclusionary value	Likely none if the patent expired in 2018

When did US Patent 6,159,498 lose exclusivity?

The patent was granted in 2000, but the grant date does not determine expiration for a post-June 8, 1995 application. Under 35 U.S.C. §154, the normal term is 20 years from the earliest effective US nonprovisional filing date, subject to adjustments.[1]

The available grant information supports the following commercial timeline:

Event	Date or status
US patent grant	December 12, 2000
Normal statutory framework	20 years from earliest effective nonprovisional filing
Nominal term	Likely ended in 2018
Current status	No current exclusivity should be assumed from the patent number alone
Orange Book status	No basis to treat the patent as an Orange Book-listed drug patent
Biosimilar relevance	None; the patent covers a small-molecule delivery device, not a biologic
Paragraph IV relevance	None unless tied to a listed drug application and an unexpired, listed patent

Patent-term adjustment can extend a patent beyond the basic 20-year calculation. Maintenance-fee nonpayment can cause an earlier lapse, although reinstatement may be available under statutory procedures.[1][3] The controlling status is the USPTO patent register and maintenance record, not a commercial product label or secondary patent database.

Is US Patent 6,159,498 listed in the Orange Book?

The patent is not naturally an Orange Book patent because its claims are directed to a pharmaceutical carrier device rather than an approved drug substance, drug product formulation, or method of use for a specific approved product.

The FDA Orange Book lists patents submitted for approved drug products under the Hatch-Waxman framework. A general platform patent covering films containing numerous unrelated pharmaceutical classes normally does not establish an Orange Book listing for every drug that could be placed in the film.[4]

The patent therefore does not independently create a Paragraph IV barrier for an ANDA applicant. An ANDA applicant would analyze patents listed for the specific reference listed drug, including drug-substance, formulation, method-of-use, and device-related patents that FDA recognizes for that product.

What Paragraph IV challenges and generic-entry risks exist?

There is no inherent Paragraph IV exposure from US 6,159,498 alone. Paragraph IV litigation requires an ANDA applicant to certify that a listed patent is invalid, unenforceable, or not infringed.[5]

A generic or branded competitor could still encounter patent risk from later patents covering:

Specific oral-film formulations;
Sublingual or buccal delivery of a particular active ingredient;
Taste masking and flavor systems;
Film thickness, drying, and manufacturing parameters;
Controlled release or multilayer release profiles;
Specific polymer ratios;
Drug-polymer complexes;
Packaging and moisture protection;
Combination products;
A named approved product or therapeutic indication.

Those later patents must be reviewed separately. US 6,159,498 cannot be used as a substitute for a product-specific freedom-to-operate search.

A generic manufacturer could design around the patent by using a different adhesive polymer system, a different backing polymer, a single-layer film, a non-mucosal dissolving strip, or a dosage form such as a tablet, gel, spray, lozenge, or conventional patch. Design-around does not resolve other patents in the oral-film field.

What patent landscape surrounds mucosal pharmaceutical films?

The relevant patent landscape has several overlapping families rather than a single dominant patent.

Polymer and film-platform patents

These patents focus on film-forming polymers, plasticizers, solvents, drying conditions, and mechanical strength. They can cover films that dissolve rapidly or remain in place on mucosal tissue.

Mucoadhesive delivery patents

These patents focus on adhesion to oral, buccal, vaginal, nasal, ocular, or gastrointestinal mucosa. They often claim polymer combinations, adhesive strength, residence time, and site-specific administration.

Active-specific formulation patents

These patents protect a particular drug in a film. Examples of common subject matter include opioid films, antiemetic films, nicotine films, antifungal films, local-anesthetic films, and antiviral films.

Manufacturing patents

Manufacturing claims may cover continuous casting, multilayer coating, solvent evaporation, drying temperature, web handling, slitting, and moisture-controlled packaging. These claims can create practical barriers even when the basic carrier patent has expired.

Product and method-of-use patents

Later patents may claim a particular strength, dosing schedule, indication, patient population, or mucosal administration method. These claims can matter during regulatory review even when the underlying film platform is old.

How does this patent compare with later oral-film estates?

US 6,159,498 is an early platform patent with a chemically defined adhesive layer and a water-soluble backing layer. Its coverage is broader by active-ingredient category than many later product patents, but narrower in its polymer architecture.

Attribute	US 6,159,498	Typical later oral-film patent
Claim focus	Layered mucosal carrier device	Specific drug, formulation, process, or indication
Active ingredient	Broad classes and long lists	Often one active ingredient
Polymer requirements	Highly specific	May use broader or different polymer combinations
Manufacturing claims	None apparent from supplied claims	Often included
Method-of-use claims	None apparent from supplied claims	Common
Regulatory linkage	General platform	More likely tied to a specific approved product
Term position	Likely expired in 2018	Depends on family and grant date
Design-around	Polymer substitution or structural changes	May require a different drug, process, or clinical use

The patent’s main historical significance is its integration of a mucoadhesive layer and a non-adhesive backing layer in a dissolvable flexible film. Its present commercial value depends on whether later patents independently cover the target product.

What litigation or licensing issues affect the patent?

The supplied claims do not identify any litigation, settlement, assignment, license, continuation, reexamination, inter partes review, or terminal disclaimer. Those matters cannot be inferred from the claim language.

A complete ownership and enforcement analysis would distinguish:

Original applicant and current assignee;
Recorded assignments;
Maintenance-fee status;
Patent-term adjustment;
Reexamination certificates;
Post-grant proceedings;
Federal district-court litigation;
ITC investigations;
License agreements and settlement terms.

A patent license would not restore an expired patent’s exclusionary term, although it could affect historical royalties, covenants, know-how, confidential information, or related unexpired patent families.

What technical inconsistencies appear in the claims?

Several drafting issues should be considered during claim construction:

Claim 4 uses “steroidal anti-inflammatory agent,” while the listed compounds in claim 5 include spelling errors such as “predonisolone” and “diproprionate.”
Claim 6 excludes “dyclonine HCl,” while claim 7 lists “dyclonine” without the hydrochloride designation.
Claim 25 refers to a “thymadine kinase inhibitor,” likely intending “thymidine kinase inhibitor.”
Claim 10 uses “bactericide,” while many listed compounds may also be characterized as antiseptics or antimicrobial agents.
Claim 26 measures pharmaceutical content by weight of the entire carrier device, but the claim does not specify whether the calculation excludes moisture, packaging, or volatile processing components.

Typographical errors do not automatically invalidate a claim. Courts generally read claims in the context of the specification and prosecution history. An error that creates ambiguity can raise indefiniteness or claim-construction issues under 35 U.S.C. §112.[6]

What is the commercial relevance of the patent today?

The patent does not appear to create current exclusivity for acetaminophen, ibuprofen, lidocaine, acyclovir, antibiotics, antihistamines, or other listed agents. Those compounds are separately governed by their own regulatory, formulation, labeling, and patent histories.

The key commercial risks are therefore indirect:

A company may rely on the expired platform while infringing a later active-specific patent.
A product may avoid US 6,159,498 but still fall within a later polymer or manufacturing claim.
A film product may require an FDA pathway determined by active ingredient, indication, dosage, and marketing status.
A foreign counterpart may have had a different expiration date, prosecution history, or legal status.
Know-how and manufacturing controls may remain commercially valuable after patent expiration.

Geographic freedom to operate must be analyzed country by country. US expiration does not terminate corresponding foreign rights.

Key Takeaways

US 6,159,498 claims a two-layer biodegradable, water-soluble mucosal film.
Claim 1 requires hydroxyethyl cellulose, polyacrylic acid, and sodium carboxymethyl cellulose in the adhesive layer.
The backing layer must be water-soluble, non-adhesive, and contain hydroxyethyl cellulose.
The patent covers a delivery platform, not the listed drugs as standalone compositions.
Claims 2 through 25 add broad therapeutic categories and named pharmaceutical agents.
Claims 26 and 27 add drug-loading ranges of approximately 0.001%-30% and 0.005%-20% by weight.
The patent’s ordinary US term likely ended in 2018, subject to USPTO term and maintenance records.
The patent does not itself create a current Orange Book or Paragraph IV barrier.
No biosimilar issue applies because the claims concern a small-molecule delivery device.
Later patents covering specific drugs, polymer systems, manufacturing methods, indications, and packaging remain the primary current freedom-to-operate risks.
The most straightforward design-around strategies involve changing the polymer system, eliminating the two-layer architecture, or using a non-mucosal dosage form.

FAQs About US Patent 6,159,498

Can a company sell a buccal film containing lidocaine after US 6,159,498 expired?

Yes, expiration of the patent removes its US patent barrier, but the product must still be screened against later active lidocaine-film patents, manufacturing patents, regulatory requirements, and third-party rights.

Does claim 3 cover ibuprofen tablets or ibuprofen gels?

No. Claim 3 requires the layered pharmaceutical carrier device of claim 1. An ordinary ibuprofen tablet or gel does not satisfy the claimed film architecture.

Does a film using carbomer instead of polyacrylic acid infringe claim 1?

It would not literally meet the express polyacrylic-acid limitation. Equivalents analysis could raise a separate issue, but it would depend on the patent record, the substituted polymer, and the prosecution history.

Are foreign patents corresponding to US 6,159,498 automatically expired?

No. Foreign patent terms, filing dates, national-phase events, maintenance requirements, and legal-status rules differ by jurisdiction.

Can the expired patent still be cited against a later oral-film patent?

Yes. An expired patent remains prior art for novelty and obviousness analysis if it was publicly available before the relevant later patent’s effective filing date.[7]

References

United States Code. (2024). 35 U.S.C. §154: Contents and term of patent; provisional rights.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance.
United States Code. (2024). 35 U.S.C. §41: Patent fees; §50: Patent fees and patent-term maintenance.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
United States Code. (2024). 21 U.S.C. §355(j): Abbreviated applications for new drugs.
United States Code. (2024). 35 U.S.C. §112: Specification.
United States Code. (2024). 35 U.S.C. §§102-103: Conditions for patentability; novelty and obviousness.
United States Patent No. 6,159,498. (2000). Biodegradable, water-soluble pharmaceutical carrier device. U.S. Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	229322	⤷ Start Trial
Austria	288743	⤷ Start Trial
Australia	3892401	⤷ Start Trial
Australia	3967899	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,159,498

Summary for Patent: 6,159,498